Assoc. Prof. Mario Tan, PhD, Chair of the Department of Chemistry of the College of Science, has been selected as a 2016 Novartis Next Generation Scientist Program Fellow.
He is one of the only two awardees from the Philippines. After having been nominated by the Philippine Council for Health Research and Development of the Department of Science and Technology, Dr. Tan presented his research thrusts on Drug Discovery and Development as well as his research projects and interests to a distinguished Board of Judges during the Selection Process last November 24, 2015 at the Makati Diamond Residences Hotel.
The Board of Judges comprised of DOST Undersecretary for Research and Development Amelia P. Guevara, PCHRD Executive Director Jaime C. Montoya, the two Novartis Institute of Tropical Diseases Senior Investigators Dr. Jan Jiricek and Dr. Shew Peng Lim, Novartis Healthcare Philippines Chief Scientific Officer Dr. Francis Domingo, and Novartis Philippines Market Access & Corporate Affairs Director Ms. Christine Fajardo, the Market Access &.
The Novartis Next Generation Scientist Program is an intensive internship program for motivated research scientists from emerging countries. The 3-month program (1 June to 31 August), hosted at Novartis’ research site in Basel, Switzerland and Singapore, is designed to foster both their scientific and professional development.
Guided by Novartis mentors, the fellows work on a jointly agreed-upon, pre-competitive scientific or clinical project and also participate in a leadership development program designed to enhance their decision-making and communication skills. This internship aims to build scientific and leadership capability in emerging countries by enhancing the skills of local scientists and by facilitating the knowledge transfer to their wider scientific communities upon their return home.
The relationships forged between Novartis and the interns’ home institutions will further the endeavor to create next-generation medicines to ease suffering and improve quality of life for patient populations around the world.
No comments:
Post a Comment